Serum neuropeptide Y (NPY) and PACAP levels changed significantly during acute pulmonary exacerbations in cystic fibrosis patients, suggesting neuropeptide involvement in CF lung inflammation.
Neuropeptides in CFNPY and PACAP levels shifted during CF lung exacerbations, suggesting neuropeptide involvement in this genetic lung disease
What the researchers found
NPY and PACAP serum levels changed significantly during CF pulmonary exacerbations and correlated with clinical outcomes, linking neuropeptide signaling to CF lung inflammation.
Why it matters
CF lung exacerbations are the main cause of disease progression. If neuropeptides contribute to lung inflammation, targeting them could reduce exacerbation severity and slow lung decline.
The numbers in context
20 CF patients, mean age 8.83 years (±4.37). Three neuropeptides measured: substance P, NPY, PACAP. Blood drawn at admission and 2 weeks post-antibiotics.
How the study worked
Measured serum NPY and PACAP levels in CF patients during acute pulmonary exacerbations and after treatment. Correlated neuropeptide levels with clinical outcomes.
Who was studied
20 cystic fibrosis patients (mean age 8.83 years) with pulmonary exacerbations
What this study cannot tell us
Small CF patient cohort typical for rare disease studies. Neuropeptide changes may be secondary to inflammation rather than causative. Correlation does not prove therapeutic potential.
How to read the evidence
Preliminary evidence: observational study in CF patients with neuropeptide-outcome correlations.
When this study was published
Published in 2025. Novel connection between neuropeptide biology and CF lung disease.
The bigger picture
Neuropeptides are increasingly recognized as modulators of inflammatory responses across many organs. This study extends the connection to CF lung disease, suggesting the neuro-immune axis plays an underappreciated role in this genetic condition.
Questions still open
- Could neuropeptide modulation reduce CF exacerbation severity?
- Do NPY and PACAP levels predict impending CF exacerbations?
- Would NPY/PACAP measurements add to current CF biomarker panels?
Common questions
What do neuropeptides have to do with cystic fibrosis?
Could this lead to new CF treatments?
Read the original research
Treatment of cystic fibrosis pulmonary exacerbation and serum levels of neuropeptides.
Journal of immunoassay & immunochemistry, 46(6), 637-653
Citation
Al-Keilani, Maha S; Bdeir, Roba; Almomani, Basima A; Awad, Samah; Hammouri, Hanan; Al Shalakhti, Tala; Dahabreh, Muna M; Ajlony, Mohammad-Jaafar A. (2025). Treatment of cystic fibrosis pulmonary exacerbation and serum levels of neuropeptides.. Journal of immunoassay & immunochemistry, 46(6), 637-653. https://doi.org/10.1080/15321819.2025.2580418